MET and neoplasm: Both compounds at nanomolar concentrations reduced the level of the phosphorylated form of c-Met protein and were able to block the c-Met accumulation in tumor cells at higher concentrations, indicating the high potency of novel anticancer cabozantinib-based PROTACs.